<DOC>
	<DOCNO>NCT02691949</DOCNO>
	<brief_summary>Past literature show encouraging effect mycophenolate dryness symptom quality life patient Sjogren 's syndrome . Mycophenolate also excellent immunomodulation effect lupus nephritis . Currently Mycophenolate use lupus nephritis organ transplant . It unknown whether low dosage mycophenolate mofetil could use improve ocular dryness oral dryness patient Sjogren 's syndrome .</brief_summary>
	<brief_title>Efficacy Safety Mycophenolate Mofetil subjectswithSjogren 's Syndrome</brief_title>
	<detailed_description>Sjogren 's syndrome one common autoimmune disease Taiwan . It characterize keratoconjunctivitis sicca xerostomia . Although well establish Sjogren 's syndrome cause infiltration destruction lacrimal gland salivary gland lymphocytic cell , effective treatment patient ' symptom lack . Hydroxychloroquine well-studied medication Sjogren 's syndrome . However , recent clinical trial show disappointing effect hydroxychloroquine Sjogren 's syndrome . Thus unmet need find effective treatment patient 's bothering symptom . Mycophenolate selective inhibitor inosinemonophosphate dehydrogenase lead inhibition de novo pathway nucleotide synthesis . The antiproliferative effect mycophenolate mainly affect activate T B lymphocytes proliferation cell critically dependent de novo purine synthesis compare eukaryotic cell . Since lymphocyte suggest play pivotal role inflammation immunopathogenesis Sjogren 's syndrome , mycophenolate might promise agent treatment Sjogren 's syndrome . Past literature show encouraging effect mycophenolate dryness symptom quality life patient Sjogren 's syndrome . Mycophenolate also excellent immunomodulation effect lupus nephritis . Currently mycophenolate use lupus nephritis organ transplant . It unknown whether low dosage mycophenolate could use improve ocular dryness oral dryness patient Sjogren 's syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Diagnosis primary Sjogren 's syndrome base 2002 AmericanEuropean Consensus criteria 2 . Aged 20 75 year 3 . Stable dos oral corticosteroid ( ≦5mg/d ) least 4 week enrollment 4 . Intolerance inadequate response hydroxychloroquine ( pilocarpine cevimeline ) , define less 50mm least 2 VAS include : 1. global assessment : 0mm ( bad ) 100mm ( good ) 2. pain : 0mm ( bad ) 100mm ( good ) 3. fatigue : 0mm ( bad ) 100mm ( good ) 4. xerostomia : 0mm ( bad ) 100mm ( good ) 5 . Adequate contraception patient childbearing potential 1 . Receiving biologics 6 previous month immunosuppressant ( methotrexate , cyclophosphamide , cyclosporine , azathioprine , mycophenolate mofetil ( MMF ) , mycophenolate sodium , leflunomide , penicillamine ) previous month 2 . Any one laboratory abnormality : 1 . Serum creatinine ≥2 mg/dl 2. aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) 1.5 x upper normal range laboratory 3 . Leukopenia ( WBC &lt; 4000/μl ) 4 . Hb ≤ 9 g/dl ( 5.6 mmol/l ) males 8.5 g/dl ( 5.3 mmol/l ) females 5 . Neutrophil le 1.5 x 109/l 6 . Platelet count le 150 x 109/l 3 . History autoimmune diseases 4 . Use topical cyclosporine eyedrop , antihistamine , anticholinergic , antidepressant , antipsychotic drug possible effect ocular dryness oral dryness within 1 month 5 . Pregnant lactate woman 6 . Previous current malignancy adequately control less 5 year , hepatitis B , hepatitis C , HIV infection , tuberculosis , diabetes 7 . Subjects serious infection require hospitalization within last 12 month 8 . Subjects herpes zoster cytomegalovirus resolve less 2 month enrollment 9 . Subjects receive live vaccine within 3 month 10 . Underlying cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal , haematological neurological condition , chronic latent infectious disease immune deficiency place patient unacceptable risk participation study 11 . History recur chronic infection underlie condition may predispose patient serious infection 12 . Subjects impair , incapacitate , incapable completing studyrelated assessment 13 . History allergy mycophenolate sodium 14 . Nausea , vomit , diarrhea within 1 week enrollment 15 . History psychosis , seizure , retinopathy 16 . Infection 2 week enrollment 17 . Heart rate &lt; 60/min rest</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>